What question did this study set out to answer?

To evaluate the immunogenicity of a two-dose enhanced-potency inactivated poliovirus vaccine combined with DPT in infants and examine the effects of age, dose intervals, and maternal antibodies.

October 1, 1985Archives of Pediatrics and Adolescent Medicine

Antibody Response of Infants to Two Doses of Inactivated Poliovirus Vaccine of Enhanced Potency

View Full Paper

Ask AI

Bookmark

Why the study?

Does a two-dose schedule of enhanced potency inactivated poliovirus vaccine produce adequate antibody responses in infants?

Population

214 infants (100 received doses 4 weeks apart, 114 received doses 8 weeks apart)

Comparison

New formulation of inactivated poliovirus… vs Comparison between 4-week and 8-week dosing…

Design

Cohort

Authors

ESEric A. F. SimõesColorado School of Public Health

Discussion

Member takes

Implication

Supports two-dose enhanced-potency IPV in infants ≥8 weeks; leaves open randomized confirmation of clinical protection.

Key Points

To evaluate the immunogenicity of a two-dose enhanced-potency inactivated poliovirus vaccine combined with DPT in infants and examine the effects of age, dose intervals, and maternal antibodies.
Administered two doses of an enhanced-potency DPT-IPV vaccine (40, 8, and 32 D-antigen units for types 1, 2, and 3) either four weeks apart (N=100) or eight weeks apart (N=114) to infants aged 6 to 45 weeks.
Measured pre- and post-immunization neutralizing antibody titers against poliovirus types 1, 2, and 3, analyzing responses by age cohort, dose interval, and maternal antibody presence.
Seroconversion rates reached 90% to 100% for poliovirus types 1 and 3 regardless of infant age or interval between doses.
Seroconversion to type 2 was below 84% in infants aged 6–7 weeks, 88% to 95% in infants aged 8–12 weeks, and 90% to 100% in infants aged 13–45 weeks.
Preexisting maternal antibodies reduced seroconversion rates and geometric mean titers, with optimal immunogenicity achieved in infants aged 8 weeks or older receiving doses eight weeks apart.

Structured PICO

Does a two-dose schedule of enhanced potency inactivated poliovirus vaccine produce adequate antibody responses in infants?

Population

214 infants (100 received doses 4 weeks apart, 114 received doses 8 weeks apart)

Intervention

New formulation of inactivated poliovirus vaccine (40, 8, and 32 D-antigen units of types 1, 2, and 3) combined with diphtheria-pertussis-tetanus vaccines, administered as two doses

Comparator

Comparison between 4-week and 8-week dosing intervals, as well as age groups and presence of maternal antibodies

Outcome

Antibody titers against the three types of polioviruses (seroconversion rates and geometric mean titers)surrogate

A two-dose schedule of enhanced potency inactivated poliovirus vaccine given eight weeks apart is highly immunogenic in infants 8 weeks of age or older.

Cite This Study

Eric A. F. Simões (1985) studied this question.

synapsesocial.com/papers/6a6f23ff78a11c550e08d095 https://doi.org/10.1001/archpedi.1985.02140120023021

View Full Paper

Ask AI

Bookmark